Drug Profile
TAK 531
Alternative Names: AGT 182; IgG iduronate 2 sulfatase fusion protein; Recombinant human insulin receptor monoclonal antibody-fused iduronate 2 sulfatase; SHP 631; TAK-531Latest Information Update: 11 May 2020
Price :
$50
*
At a glance
- Originator ArmaGen Technologies
- Class Iduronate sulfatases; Immunoglobulin fusion proteins; Monoclonal antibodies
- Mechanism of Action Iduronate sulfatase replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I/II Mucopolysaccharidosis II
Most Recent Events
- 11 May 2020 TAK 531 is still in phase-I/II trials for Mucopolysaccharidosis-II in Germany, Philippines, USA (ArmaGen Technologies pipeline, May 2020)
- 21 Apr 2020 ArmaGen Technologies has been acquired by JCR Pharmaceuticals
- 28 Aug 2019 No recent reports of development identified for phase-I/II development in Mucopolysaccharidosis-II in Germany (IV, Infusion)